Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anais Badia

Dermatology Fort Myers, FL Doctor of Osteopathy

NPI 1609051887 CMS profile 1006865

13691 Metropolis Avenue, Fort Myers, FL 33912

Open in the dashboard

General payments

$9,048

144 records reported · program years 2019–2025

Research payments

$79,897

Paid to them · 100 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$753,683 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Anais Badia of Fort Myers, FL is reported in the CMS Open Payments database as having received $9,048 across 144 general payments and $79,897 in research payments paid to them. Separately, studies naming them as principal investigator received $753,683 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,119 36
2024 General $1,088 40
2024 Research $1,105 2
2023 General $839 38
2022 General $420 21
2022 Research $8,136 4
2021 General $22 1
2021 Research $11,736 5
2020 Research $30,904 22
2019 General $5,560 8
2019 Research $28,016 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anais Badia
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Anais Badia were reported at $1,119. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Anais Badia Dermatology median Middle half National median
2019 $5,560 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $22 $377 $108–$1,108 $132
2022 $420 $514 $143–$1,391 $149
2023 $839 $607 $159–$1,674 $160
2024 $1,088 $751 $204–$1,903 $164
2025 $1,119 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $5,809 20 payments
  2. AbbVie, Inc. $568 28 payments
  3. Janssen Biotech, Inc. $461 15 payments
  4. Arcutis Biotherapeutics, Inc. $257 10 payments
  5. Regeneron Healthcare Solutions, Inc. $208 4 payments
  6. UCB, Inc. $194 3 payments
  7. Galderma Laboratories, L.P. $191 5 payments
  8. Genzyme Corporation $166 7 payments
  9. Amgen Inc. $159 3 payments
  10. Lilly USA, LLC $157 6 payments
  11. Other $878 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,250 2 payments
  2. Food and Beverage $3,495 137 payments
  3. Education $303 5 payments
Products named General payments · program years 2019–2025
  1. EUCRISA $5,746 17 payments
  2. TREMFYA $436 13 payments
  3. CIBINQO $317 15 payments
  4. SKYRIZI $262 13 payments
  5. RINVOQ $241 12 payments
  6. Zoryve $237 9 payments
  7. DUPIXENT $220 9 payments
  8. Bimzelx $194 3 payments
  9. LITFULO $170 8 payments
  10. Otezla $159 3 payments
  11. Other $2,485 109 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Ichnos Sciences Inc. $50,776 31 payments
  2. Glenmark Pharmaceuticals Inc. $28,016 67 payments
  3. Eli Lilly and Company $1,105 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,262

Median for Dermatology: 534

Drug cost

$377,409

Median for Dermatology: $67,151

Branded share of claims

7.4%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Sensoready (2 Pens) Secukinumab Brand 17 $120,419
Humira(Cf) Pen Adalimumab Brand 15 $104,502
Dupixent Syringe Dupilumab Brand 13 $59,516
Otezla Apremilast Brand 12 $58,788
Pimecrolimus Generic 28 $6,747
Clobetasol Propionate Generic 71 $3,655
Metronidazole Generic 69 $3,339
Fluocinonide Generic 76 $2,866
Calcipotriene Generic 19 $2,613
Cimetidine Generic 14 $2,132

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$183,127

Of which drugs: $339

Medicare patients

885

Average age 74

Services billed

4,646

529 women, 356 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 49%
Ischemic heart disease 29%
Diabetes 20%
Chronic kidney disease 17%
Depression 17%
Osteoporosis 16%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 20 39 $28

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $180
$180 — —
Otezla
  • Amgen Inc. $132
$132 12 —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $69
  • GENZYME CORPORATION $51
$119 13 —
RINVOQ
  • AbbVie, Inc. $97
$97 — —
SKYRIZI
  • AbbVie, Inc. $89
$89 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

244 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record